October 31, 2019 06:58 AM EDTUpdated 09:48 AM
R&D

Mer­ck­'s last crack at sal­vaging a $2.5B ju­ry ver­dict in hep C patent show­down is shot down by ap­peals court

Jason Mast

Editor

In De­cem­ber 2013, Gilead an­nounced the first pill that could cure he­pati­tis C. The same week, Idenix Phar­ma­ceu­ti­cals an­nounced it was su­ing Gilead for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times